Myocardial Infarction News and Research

RSS

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

31 Jul 2014

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone).

30 Jul 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

University of Leicester receives funding from two Masonic charities for heart study

A University of Leicester research project has received vital philanthropic funding for the second year from two Masonic charities.

23 Jul 2014

BP variability may be ‘CV risk integrator’

Increased variability in blood pressure may be an indicator of overall cardiovascular risk rather than being a risk factor per se, suggest researchers.

21 Jul 2014

IL-10 enhances positive benefits of transplanted allogenic SMCs to repair cardiac tissues after MI

The long-term, positive benefits of transplanted allogenic (other-donated) smooth muscle cells (SMCs) to repair cardiac tissues after myocardial infarction (MI) have been enhanced by the addition of interleukin 10 (IL-10) to the transplanted cells, report researchers in Canada.

21 Jul 2014

Common genetic variation in gene may modify cardiovascular benefit of aspirin

Aspirin is the gold standard for antiplatelet therapy and a daily low-dose aspirin is widely prescribed for the prevention of cardiovascular disease.

21 Jul 2014

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

18 Jul 2014

Pain control in osteoarthritis patients

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.

9 Jul 2014

Findings shed light on possible role of affective temperaments in cardiovascular morbidity

Temperament has been traditionally associated with high blood pressure. A new study that has appeared in the current issue of Psychotherapy and Psychosomatics has substantiated this issue.

7 Jul 2014

Pneumonia patients treated with azithromycin face lower risk of death, slightly increased risk of heart attack

In a study that included nearly 65,000 older patients hospitalized with pneumonia, treatment that included azithromycin compared with other antibiotics was associated with a significantly lower risk of death and a slightly increased risk of heart attack, according to a study in the June 4 issue of JAMA.

4 Jul 2014

Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease.

19 Jun 2014

Counseling, medication management by pharmacist can lower hospital readmissions

Getting discharged from the hospital and then having to go right back in again can be emotionally draining for a patient and their family. It can also cause financial strain for all involved - the patient, the hospital system and the insurers-including Medicaid and Medicare, which are taxpayer funded.

19 Jun 2014

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.

18 Jun 2014

Recreational football training sessions lower blood pressure and improves heart function

The studies, published in the acclaimed Scandinavian Journal of Medicine & Science in Sports, show that 24 weeks of twice-weekly recreational football training sessions lower blood pressure and improves heart function in men with high blood pressure and men with type 2 diabetes.

13 Jun 2014

FCVB 2014 to feature cutting edge research in basic cardiovascular science

Cutting edge research in basic cardiovascular science will be presented at Frontiers in CardioVascular Biology (FCVB) 2014, held 4-6 July at the Palau de Congressos de Catalunya in Barcelona, Spain.

5 Jun 2014

STENTYS signs agreement to acquire assets of Cappella Peel Away

STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.

5 Jun 2014

Researchers develop virtual platform that measures level of addiction of smokers

In Mexico, 21.7 percent of the population smokes, which is associated with 95 percent of  lung cancer cases and the development of 29 more different conditions.

31 May 2014

Blood gene expression profile identifies patients with elevated risk of cardiovascular death

A study of 338 patients with coronary artery disease has identified a gene expression profile associated with an elevated risk of cardiovascular death. Used with other indicators such as biochemical markers and family history, the profile - based on a simple blood test - may help identify patients who could benefit from personalized treatment and counseling designed to address risk factors.

30 May 2014

Consistent glycaemic control wards off diabetic complications

Variability in glycaemic control is associated with both microvascular and macrovascular events in patients with Type 2 diabetes, shows an analysis of the ADVANCE trial.

23 May 2014

Myocardial Infarction News and Research

Regeneron announces FDA approval of EYLEA Injection for DME treatment

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

University of Leicester receives funding from two Masonic charities for heart study

BP variability may be ‘CV risk integrator’

IL-10 enhances positive benefits of transplanted allogenic SMCs to repair cardiac tissues after MI

Common genetic variation in gene may modify cardiovascular benefit of aspirin

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Pain control in osteoarthritis patients

Findings shed light on possible role of affective temperaments in cardiovascular morbidity

Pneumonia patients treated with azithromycin face lower risk of death, slightly increased risk of heart attack

Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

Counseling, medication management by pharmacist can lower hospital readmissions

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Recreational football training sessions lower blood pressure and improves heart function

FCVB 2014 to feature cutting edge research in basic cardiovascular science

STENTYS signs agreement to acquire assets of Cappella Peel Away

Researchers develop virtual platform that measures level of addiction of smokers

Blood gene expression profile identifies patients with elevated risk of cardiovascular death

Consistent glycaemic control wards off diabetic complications

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News